DF Dent & Co. Inc. Sells 941 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

DF Dent & Co. Inc. trimmed its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 1.7% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 53,272 shares of the company's stock after selling 941 shares during the quarter. DF Dent & Co. Inc. owned 0.07% of IDEXX Laboratories worth $22,025,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in IDXX. Cranbrook Wealth Management LLC boosted its holdings in shares of IDEXX Laboratories by 7.0% during the 4th quarter. Cranbrook Wealth Management LLC now owns 382 shares of the company's stock valued at $158,000 after acquiring an additional 25 shares in the last quarter. Perigon Wealth Management LLC lifted its stake in IDEXX Laboratories by 1.8% in the fourth quarter. Perigon Wealth Management LLC now owns 1,474 shares of the company's stock valued at $632,000 after buying an additional 26 shares during the period. Summit Trail Advisors LLC increased its stake in shares of IDEXX Laboratories by 3.3% in the 4th quarter. Summit Trail Advisors LLC now owns 810 shares of the company's stock valued at $335,000 after acquiring an additional 26 shares in the last quarter. IFP Advisors Inc raised its holdings in shares of IDEXX Laboratories by 3.6% during the fourth quarter. IFP Advisors Inc now owns 903 shares of the company's stock valued at $373,000 after purchasing an additional 31 shares during the period. Finally, Cape Cod Five Cents Savings Bank grew its stake in IDEXX Laboratories by 0.5% in the third quarter. Cape Cod Five Cents Savings Bank now owns 6,344 shares of the company's stock valued at $3,091,000 after acquiring an additional 32 shares during the period. 87.84% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

Insider Buying and Selling

In related news, Director M Anne Szostak sold 3,000 shares of the company's stock in a transaction dated Friday, February 7th. The shares were sold at an average price of $465.94, for a total value of $1,397,820.00. Following the transaction, the director now owns 3,061 shares in the company, valued at $1,426,242.34. The trade was a 49.50 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP George Fennell sold 9,986 shares of the business's stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $462.53, for a total value of $4,618,824.58. Following the sale, the executive vice president now owns 8,176 shares of the company's stock, valued at approximately $3,781,645.28. This represents a 54.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 2.11% of the stock is owned by insiders.

Analyst Ratings Changes

Several equities analysts recently weighed in on IDXX shares. Barclays raised their price target on shares of IDEXX Laboratories from $481.00 to $520.00 and gave the company an "overweight" rating in a research report on Tuesday, February 4th. StockNews.com upgraded shares of IDEXX Laboratories from a "hold" rating to a "buy" rating in a research note on Friday. Bank of America upped their price objective on IDEXX Laboratories from $475.00 to $535.00 and gave the company a "neutral" rating in a research note on Tuesday, February 4th. Morgan Stanley cut their price objective on shares of IDEXX Laboratories from $559.00 to $550.00 and set an "overweight" rating for the company in a report on Wednesday, January 29th. Finally, Piper Sandler upped their target price on shares of IDEXX Laboratories from $435.00 to $510.00 and gave the stock a "neutral" rating in a research report on Monday, February 10th. Three research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $533.75.

IDEXX Laboratories Stock Up 0.3 %

IDXX traded up $1.23 on Tuesday, hitting $380.22. The company had a trading volume of 322,647 shares, compared to its average volume of 596,768. IDEXX Laboratories, Inc. has a 52-week low of $366.50 and a 52-week high of $548.88. The stock has a fifty day simple moving average of $434.58 and a 200-day simple moving average of $438.33. The company has a debt-to-equity ratio of 0.28, a current ratio of 1.31 and a quick ratio of 0.95. The firm has a market capitalization of $30.81 billion, a P/E ratio of 35.78, a P/E/G ratio of 3.41 and a beta of 1.50.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.